Menopause treatment passes late stage test with flying colors

8 January 2024
bayer_big

German pharmaceutical company Bayer (BAYN: DE) has announced positive top-line results from the Phase III OASIS 1 and 2 studies.

The company has been evaluating the efficacy and safety profile of the elinzanetant, a dual NK-1 and 3 receptor antagonist, as a non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause.

The therapy was compared with placebo in the trials, which successfully met all four primary endpoints, demonstrating statistically significant reductions in VMS after four and 12 weeks.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical